Selected research
Market Structure
Global APOL1 Mediated Kidney Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global APOL1 Mediated Kidney Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for APOL1 Mediated Kidney Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for APOL1 Mediated Kidney Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for APOL1 Mediated Kidney Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for APOL1 Mediated Kidney Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of APOL1 Mediated Kidney Disease include Teva Pharmaceuticals, Novartis, ZyVersa Therapeutics, Vertex Pharmaceuticals, Travere Therapeutics, Ionis Pharmaceuticals, GlaxoSmithKline and ChemoCentryx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global APOL1 Mediated Kidney Disease market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of APOL1 Mediated Kidney Disease and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents APOL1 Mediated Kidney Disease revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the APOL1 Mediated Kidney Disease market size, projected growth trends, production technologies, key applications, and end-use industries.
APOL1 Mediated Kidney Disease Segment by Company
Teva Pharmaceuticals
Novartis
ZyVersa Therapeutics
Vertex Pharmaceuticals
Travere Therapeutics
Ionis Pharmaceuticals
GlaxoSmithKline
ChemoCentryx
APOL1 Mediated Kidney Disease Segment by Type
Small Molecule
Gene Modification
Nucleic Acid Therapies
Others
APOL1 Mediated Kidney Disease Segment by Application
Chronic Kidney Disease
End Stage Kidney Disease
APOL1 Mediated Kidney Disease Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global APOL1 Mediated Kidney Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of APOL1 Mediated Kidney Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of APOL1 Mediated Kidney Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of APOL1 Mediated Kidney Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global APOL1 Mediated Kidney Disease industry.
Chapter 3: Detailed analysis of APOL1 Mediated Kidney Disease companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, APOL1 Mediated Kidney Diseaserevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecule
- Gene Modification
- Nucleic Acid Therapies
- Others
Applications
- Chronic Kidney Disease
- End Stage Kidney Disease
Companies covered
- Teva Pharmaceuticals
- Novartis
- ZyVersa Therapeutics
- Vertex Pharmaceuticals
- Travere Therapeutics
- Ionis Pharmaceuticals
- GlaxoSmithKline
- ChemoCentryx
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Small Molecule
- 1.2.3 Gene Modification
- 1.2.4 Nucleic Acid Therapies
- 1.2.5 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Chronic Kidney Disease
- 1.3.3 End Stage Kidney Disease
- 1.4 Global Market Growth Prospects
- 1.5 Global APOL1 Mediated Kidney Disease Growth Trends by Region
- 1.5.1 Global APOL1 Mediated Kidney Disease Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 APOL1 Mediated Kidney Disease Market Size by Region (2021-2026)
- 1.5.3 APOL1 Mediated Kidney Disease Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global APOL1 Mediated Kidney Disease Market Dynamics
- 2.1 APOL1 Mediated Kidney Disease Industry Trends
- 2.2 APOL1 Mediated Kidney Disease Industry Drivers
- 2.3 APOL1 Mediated Kidney Disease Industry Opportunities and Challenges
- 2.4 APOL1 Mediated Kidney Disease Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global APOL1 Mediated Kidney Disease Revenue by Company (2021-2026)
- 3.2 Global APOL1 Mediated Kidney Disease Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global APOL1 Mediated Kidney Disease Key Company Head office and Area Served
- 3.4 Global APOL1 Mediated Kidney Disease Company, Product Type & Application
- 3.5 Global APOL1 Mediated Kidney Disease Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global APOL1 Mediated Kidney Disease Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 APOL1 Mediated Kidney Disease Players Market Share by Revenue in 2025
- 3.6.3 2025 APOL1 Mediated Kidney Disease Tier 1, Tier 2, and Tier 3
4 APOL1 Mediated Kidney Disease Market by Type
- 4.1 Global APOL1 Mediated Kidney Disease Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global APOL1 Mediated Kidney Disease Market Size by Type (2021-2032)
- 4.3 Global APOL1 Mediated Kidney Disease Market Size Share by Type (2021-2032)
5 APOL1 Mediated Kidney Disease Market by Application
- 5.1 Global APOL1 Mediated Kidney Disease Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global APOL1 Mediated Kidney Disease Market Size by Application (2021-2032)
- 5.3 Global APOL1 Mediated Kidney Disease Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Teva Pharmaceuticals
- 6.1.1 Teva Pharmaceuticals Company Information
- 6.1.2 Teva Pharmaceuticals Business Overview
- 6.1.3 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
- 6.1.5 Teva Pharmaceuticals Recent Developments
- 6.2 Novartis
- 6.2.1 Novartis Company Information
- 6.2.2 Novartis Business Overview
- 6.2.3 Novartis APOL1 Mediated Kidney Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Novartis APOL1 Mediated Kidney Disease Product Portfolio
- 6.2.5 Novartis Recent Developments
- 6.3 ZyVersa Therapeutics
- 6.3.1 ZyVersa Therapeutics Company Information
- 6.3.2 ZyVersa Therapeutics Business Overview
- 6.3.3 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Product Portfolio
- 6.3.5 ZyVersa Therapeutics Recent Developments
- 6.4 Vertex Pharmaceuticals
- 6.4.1 Vertex Pharmaceuticals Company Information
- 6.4.2 Vertex Pharmaceuticals Business Overview
- 6.4.3 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
- 6.4.5 Vertex Pharmaceuticals Recent Developments
- 6.5 Travere Therapeutics
- 6.5.1 Travere Therapeutics Company Information
- 6.5.2 Travere Therapeutics Business Overview
- 6.5.3 Travere Therapeutics APOL1 Mediated Kidney Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Travere Therapeutics APOL1 Mediated Kidney Disease Product Portfolio
- 6.5.5 Travere Therapeutics Recent Developments
- 6.6 Ionis Pharmaceuticals
- 6.6.1 Ionis Pharmaceuticals Company Information
- 6.6.2 Ionis Pharmaceuticals Business Overview
- 6.6.3 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
- 6.6.5 Ionis Pharmaceuticals Recent Developments
- 6.7 GlaxoSmithKline
- 6.7.1 GlaxoSmithKline Company Information
- 6.7.2 GlaxoSmithKline Business Overview
- 6.7.3 GlaxoSmithKline APOL1 Mediated Kidney Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 GlaxoSmithKline APOL1 Mediated Kidney Disease Product Portfolio
- 6.7.5 GlaxoSmithKline Recent Developments
- 6.8 ChemoCentryx
- 6.8.1 ChemoCentryx Company Information
- 6.8.2 ChemoCentryx Business Overview
- 6.8.3 ChemoCentryx APOL1 Mediated Kidney Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 ChemoCentryx APOL1 Mediated Kidney Disease Product Portfolio
- 6.8.5 ChemoCentryx Recent Developments
7 North America
- 7.1 North America APOL1 Mediated Kidney Disease Market Size (2021-2032)
- 7.2 North America APOL1 Mediated Kidney Disease Market Size by Type
- 7.2.1 North America APOL1 Mediated Kidney Disease Market Size by Type (2021-2026)
- 7.2.2 North America APOL1 Mediated Kidney Disease Market Size by Type (2027-2032)
- 7.2.3 North America APOL1 Mediated Kidney Disease Market Share by Type (2021-2032)
- 7.3 North America APOL1 Mediated Kidney Disease Market Size by Application
- 7.3.1 North America APOL1 Mediated Kidney Disease Market Size by Application (2021-2026)
- 7.3.2 North America APOL1 Mediated Kidney Disease Market Size by Application (2027-2032)
- 7.3.3 North America APOL1 Mediated Kidney Disease Market Share by Application (2021-2032)
- 7.4 North America APOL1 Mediated Kidney Disease Market Size by Country
- 7.4.1 North America APOL1 Mediated Kidney Disease Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 7.4.3 North America APOL1 Mediated Kidney Disease Market Size by Country (2027-2032)
- 7.4.4 North America APOL1 Mediated Kidney Disease Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe APOL1 Mediated Kidney Disease Market Size (2021-2032)
- 8.2 Europe APOL1 Mediated Kidney Disease Market Size by Type
- 8.2.1 Europe APOL1 Mediated Kidney Disease Market Size by Type (2021-2026)
- 8.2.2 Europe APOL1 Mediated Kidney Disease Market Size by Type (2027-2032)
- 8.2.3 Europe APOL1 Mediated Kidney Disease Market Share by Type (2021-2032)
- 8.3 Europe APOL1 Mediated Kidney Disease Market Size by Application
- 8.3.1 Europe APOL1 Mediated Kidney Disease Market Size by Application (2021-2026)
- 8.3.2 Europe APOL1 Mediated Kidney Disease Market Size by Application (2027-2032)
- 8.3.3 Europe APOL1 Mediated Kidney Disease Market Share by Application (2021-2032)
- 8.4 Europe APOL1 Mediated Kidney Disease Market Size by Country
- 8.4.1 Europe APOL1 Mediated Kidney Disease Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 8.4.3 Europe APOL1 Mediated Kidney Disease Market Size by Country (2027-2032)
- 8.4.4 Europe APOL1 Mediated Kidney Disease Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China APOL1 Mediated Kidney Disease Market Size (2021-2032)
- 9.2 China APOL1 Mediated Kidney Disease Market Size by Type
- 9.2.1 China APOL1 Mediated Kidney Disease Market Size by Type (2021-2026)
- 9.2.2 China APOL1 Mediated Kidney Disease Market Size by Type (2027-2032)
- 9.2.3 China APOL1 Mediated Kidney Disease Market Share by Type (2021-2032)
- 9.3 China APOL1 Mediated Kidney Disease Market Size by Application
- 9.3.1 China APOL1 Mediated Kidney Disease Market Size by Application (2021-2026)
- 9.3.2 China APOL1 Mediated Kidney Disease Market Size by Application (2027-2032)
- 9.3.3 China APOL1 Mediated Kidney Disease Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia APOL1 Mediated Kidney Disease Market Size (2021-2032)
- 10.2 Asia APOL1 Mediated Kidney Disease Market Size by Type
- 10.2.1 Asia APOL1 Mediated Kidney Disease Market Size by Type (2021-2026)
- 10.2.2 Asia APOL1 Mediated Kidney Disease Market Size by Type (2027-2032)
- 10.2.3 Asia APOL1 Mediated Kidney Disease Market Share by Type (2021-2032)
- 10.3 Asia APOL1 Mediated Kidney Disease Market Size by Application
- 10.3.1 Asia APOL1 Mediated Kidney Disease Market Size by Application (2021-2026)
- 10.3.2 Asia APOL1 Mediated Kidney Disease Market Size by Application (2027-2032)
- 10.3.3 Asia APOL1 Mediated Kidney Disease Market Share by Application (2021-2032)
- 10.4 Asia APOL1 Mediated Kidney Disease Market Size by Country
- 10.4.1 Asia APOL1 Mediated Kidney Disease Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 10.4.3 Asia APOL1 Mediated Kidney Disease Market Size by Country (2027-2032)
- 10.4.4 Asia APOL1 Mediated Kidney Disease Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Size (2021-2032)
- 11.2 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Type
- 11.2.1 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Application
- 11.3.1 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country
- 11.4.1 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa APOL1 Mediated Kidney Disease Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst